Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3).

Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS, Gaziano JM, Giovannucci E, Gonzalez C, Haiman CA, Hallmans G, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Hunter DJ, Khaw KT, Kolonel LN, Kraft P, Ma J, Le Marchand L, Lund E, Peeters PH, Stampfer M, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Riboli E, Virtamo J, Weinstein SJ, Yeager M, Ziegler RG, Cox DG.

Carcinogenesis. 2010 Mar;31(3):455-61. doi: 10.1093/carcin/bgp307.

2.

CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).

Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F, Cox DG, Gaziano JM, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn J, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Ma J, Le Marchand L, Linseisen J, Lund E, Navarro C, Overvad K, Palli D, Peeters PH, Pike MC, Riboli E, Stampfer MJ, Thun MJ, Travis R, Trichopoulos D, Yeager M, Ziegler RG, Spencer Feigelson H, Chanock SJ.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2237-46.

3.

Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies.

Danforth KN, Hayes RB, Rodriguez C, Yu K, Sakoda LC, Huang WY, Chen BE, Chen J, Andriole GL, Calle EE, Jacobs EJ, Chu LW, Figueroa JD, Yeager M, Platz EA, Michaud DS, Chanock SJ, Thun MJ, Hsing AW.

Carcinogenesis. 2008 Mar;29(3):568-72.

PMID:
17999989
4.

Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.

Canzian F, Cox DG, Setiawan VW, Stram DO, Ziegler RG, Dossus L, Beckmann L, Blanché H, Barricarte A, Berg CD, Bingham S, Buring J, Buys SS, Calle EE, Chanock SJ, Clavel-Chapelon F, DeLancey JO, Diver WR, Dorronsoro M, Haiman CA, Hallmans G, Hankinson SE, Hunter DJ, Hüsing A, Isaacs C, Khaw KT, Kolonel LN, Kraft P, Le Marchand L, Lund E, Overvad K, Panico S, Peeters PH, Pollak M, Thun MJ, Tjønneland A, Trichopoulos D, Tumino R, Yeager M, Hoover RN, Riboli E, Thomas G, Henderson BE, Kaaks R, Feigelson HS.

Hum Mol Genet. 2010 Oct 1;19(19):3873-84. doi: 10.1093/hmg/ddq291.

5.

Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Chen YC, Kraft P, Bretsky P, Ketkar S, Hunter DJ, Albanes D, Altshuler D, Andriole G, Berg CD, Boeing H, Burtt N, Bueno-de-Mesquita B, Cann H, Canzian F, Chanock S, Dunning A, Feigelson HS, Freedman M, Gaziano JM, Giovannucci E, Sánchez MJ, Haiman CA, Hallmans G, Hayes RB, Henderson BE, Hirschhorn J, Kaaks R, Key TJ, Kolonel LN, LeMarchand L, Ma J, Overvad K, Palli D, Pharaoh P, Pike M, Riboli E, Rodriguez C, Setiawan VW, Stampfer M, Stram DO, Thomas G, Thun MJ, Travis RC, Virtamo J, Trichopoulou A, Wacholder S, Weinstein SJ.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1973-81.

6.

Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival.

Abraham JE, Harrington P, Driver KE, Tyrer J, Easton DF, Dunning AM, Pharoah PD.

Clin Cancer Res. 2009 Mar 15;15(6):2181-91. doi: 10.1158/1078-0432.CCR-08-0716.

7.

Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.

Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippmann SM, Parnes HL, Dluzniewski PJ, Isaacs WB, De Marzo AM, Drake CG, Platz EA.

Prostate. 2015 Sep;75(13):1403-18. doi: 10.1002/pros.23021.

8.

Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort.

Cheng I, Penney KL, Stram DO, Le Marchand L, Giorgi E, Haiman CA, Kolonel LN, Pike M, Hirschhorn J, Henderson BE, Freedman ML.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1993-7.

9.

Association of single nucleotide polymorphisms in the prostaglandin-endoperoxide synthase 2 (PTGS2) and phospholipase A₂ group IIA (PLA2G2A) genes with susceptibility to esophageal squamous cell carcinoma.

Liu F, Wei WQ, Cormier RT, Zhang ST, Qiao YL, Li XQ, Zhu ST, Zhai YC, Peng XX, Yan YX, Wu LJ, He D, He Y.

Asian Pac J Cancer Prev. 2014;15(4):1797-802.

10.

Common genetic variation at PTEN and risk of sporadic breast and prostate cancer.

Haiman CA, Stram DO, Cheng I, Giorgi EE, Pooler L, Penney K, Le Marchand L, Henderson BE, Freedman ML.

Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1021-5.

11.

Associations between arachidonic acid metabolism gene polymorphisms and prostate cancer risk.

Amirian ES, Ittmann MM, Scheurer ME.

Prostate. 2011 Sep 15;71(13):1382-9. doi: 10.1002/pros.21354.

PMID:
21308720
12.
13.

Genetic polymorphisms in inflammation pathway genes and prostate cancer risk.

Kwon EM, Salinas CA, Kolb S, Fu R, Feng Z, Stanford JL, Ostrander EA.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):923-33. doi: 10.1158/1055-9965.EPI-10-0994.

14.

Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists.

Schonfeld SJ, Bhatti P, Brown EE, Linet MS, Simon SL, Weinstock RM, Hutchinson AA, Stovall M, Preston DL, Alexander BH, Doody MM, Sigurdson AJ.

Cancer Causes Control. 2010 Nov;21(11):1857-66. doi: 10.1007/s10552-010-9613-7.

15.

Replication of five prostate cancer loci identified in an Asian population--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3).

Lindström S, Schumacher FR, Campa D, Albanes D, Andriole G, Berndt SI, Bueno-de-Mesquita HB, Chanock SJ, Diver WR, Ganziano JM, Gapstur SM, Giovannucci E, Haiman CA, Henderson B, Hunter DJ, Johansson M, Kolonel LN, Le Marchand L, Ma J, Stampfer M, Stevens VL, Trichopoulos D, Virtamo J, Willett WC, Yeager M, Hsing AW, Kraft P.

Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):212-6. doi: 10.1158/1055-9965.EPI-11-0870-T.

16.

Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II.

Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, De Marzo AM, Isaacs WB, Drake CG, Shugart YY, Platz EA.

Prostate. 2009 Jun 1;69(8):874-85. doi: 10.1002/pros.20933.

17.

Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium.

Gaudet MM, Barrdahl M, Lindström S, Travis RC, Auer PL, Buring JE, Chanock SJ, Eliassen AH, Gapstur SM, Giles GG, Gunter M, Haiman C, Hunter DJ, Joshi AD, Kaaks R, Khaw KT, Lee IM, Le Marchand L, Milne RL, Peeters PH, Sund M, Tamimi R, Trichopoulou A, Weiderpass E, Yang XR, Prentice RL, Feigelson HS, Canzian F, Kraft P.

Breast Cancer Res Treat. 2016 Feb;155(3):531-40. doi: 10.1007/s10549-016-3681-7.

PMID:
26802016
18.

Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk.

Zhang J, Dhakal IB, Lang NP, Kadlubar FF.

Cancer Causes Control. 2010 Sep;21(9):1437-44. doi: 10.1007/s10552-010-9571-0.

19.

IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States.

Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):747-55.

20.

Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis.

Yu KD, Chen AX, Yang C, Qiu LX, Fan L, Xu WH, Shao ZM.

Breast Cancer Res Treat. 2010 Jul;122(1):251-7. doi: 10.1007/s10549-009-0688-3.

PMID:
20033767

Supplemental Content

Support Center